Phase I SCO-240 multiple dosing study

A Randomized, Single-Center, Double-Blind, Placebo-Controlled, Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of SCO-240 in Healthy Adult Subjects

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051240252

Enrollment

Registered

2025-01-28

Start date

2025-01-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Short statue caused by growth hormone deficiency

Interventions

Once daily, 7days repeated dose of SCO-240 3mg, 10mg, 20mg, 80mg or placebo with fasted condition

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: - Gender: Male - Age: Subjects are between 18 and 65 years, inclusive, at the time of informed consent - Weight at screening: >=50 kg, body mass index (BMI) >=18.5 kg/m2 and =<25.0 kg/m2

Exclusion criteria

Exclusion criteria: - Subjects who have a present illness such as cardiovascular disease, central nervous system disease, gastrointestinal disease, hematopoietic disease, renal failure, metabolic or endocrine disorder, serious allergy, asthma, hypoxemia, hypertension, convulsion or allergic rash.

Design outcomes

Primary

Measure	Time frame
Safety and pharmacokinetics	—

Secondary

Measure	Time frame
Pharamacodynamics	—

Contacts

Public ContactBusiness Development and Corporate Operation

SCOHIA PHARMA, Inc.

info@scohia.com+81-466-27-3205

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026